Supercapsular percutaneously-assisted total hip (SuperPath) versus posterolateral total hip arthroplasty in bilateral osteonecrosis of the femoral head: a pilot clinical trial

Weikun Meng  
Sichuan University West China Hospital

Zhong Huang  
Sichuan University West China Hospital

Haoyang Wang  
Sichuan University West China Hospital

Duan Wang  
Sichuan University West China Hospital

Zeyu Luo  
Sichuan University West China Hospital

Yang Bai  
Department of Immunisation, Yunnan Center for Disease Control and Prevention

Liang Gao (lianggao22@gmail.com)  
Center of Experimental Orthopaedics, Saarland University  
https://orcid.org/0000-0003-1438-9670

Guanglin Wang  
Sichuan University West China Hospital

Zongke Zhou  
Sichuan University West China Hospital

Research article

Keywords: Osteonecrosis of the femoral head (ONFH), Total hip arthroplasty, Posterolateral approach, Supercapsular percutaneously-assisted total hip arthroplasty (SuperPath), Minimal invasive surgery, Staged surgery

Posted Date: August 30th, 2019

DOI: https://doi.org/10.21203/rs.2.13759/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Version of Record: A version of this preprint was published on December 31st, 2019. See the published version at https://doi.org/10.1186/s12891-019-3023-0.
Abstract

Background: The supercapsular percutaneously-assisted total hip arthroplasty (SuperPath) was proposed to be minimally invasive and tissue sparing with possible superior postoperative outcomes to traditional approaches of total hip arthroplasty (THA). Here, we compared the short-term outcomes of staged THA with the SuperPath or through posterolateral approach (PLA) for bilateral osteonecrosis of the femoral head (ONFH).

Methods: Patients with bilateral late-stage ONFH were prospectively recruited from our department during March 2017 to March 2018. Staged bilateral THAs with one side SuperPath and the other side PLA were performed consecutively in the same patients with right and left hips alternating within groups. The average time interval between the staged THAs was 3 months. Perioperative status (operation time, incision length, intraoperative blood loss, soft tissue damage, and length of hospital stay) and postoperative function (range of motion, pain, and hip function) were recorded and compared between the SuperPath and PLA groups within 12-month postoperatively.

Results: Four male patients (age, 51.00 ± 4.54; BMI, 21.49 ± 1.73) with bilateral alcohol-induced ONFH (Ficat III/IV) were followed up over 12 months postoperatively. Compared with the PLA, the SuperPath yielded significantly shorter incision length (7.62 vs. 11.12 cm, P = 0.049), longer operation time (103.25 vs. 66.50 min, P = 0.034), more blood loss (1108.50 vs. 843.50 ml, P = 0.023), deficient acetabular cup positioning (abduction angle, 38.75° vs. 44.50°, P = 0.035), and inferior early-term hip function (Harris hip score, 72.50 vs. 83.25, P = 0.025) at 12-month postoperatively. However, soft tissue damage, length of hospital stay, postoperative pain, postoperative range of motion, and 12-month patient satisfaction were comparable between both groups.

Conclusions: The SuperPath might not be truly minimal invasive with advantages over the PLA for total hip arthroplasty in osteonecrosis of the femoral head. More investigations are required to provide convincing favorable evidences of the SuperPath over other traditional THA approaches.

Background

Osteonecrosis of the femoral head (ONFH), a devastating morbidity mainly in mid-aged population, usually progresses to femoral head collapse and requires a total hip arthroplasty (THA) [1–4]. In Asia, ONFH accounts for approximately 50% of all THA surgeries performed annually [5–7], and the THA is effectual to improve the quality of life for patients suffering from end-stage ONFH [8]. The traditional posterolateral approach (PLA) is the most widely applied approach with excellent exposure for both primary and revision hip arthroplasty [9, 10]. However, previous studies reported high risks of postoperative dislocations and periprosthetic fractures associated with the posterior approach possibly due to the extensive intraoperative impairment of periarticular soft tissues, particularly the external rotors and joint capsule [11–13].
To minimize the overall surgical aggression, the supercapsular percutaneously-assisted total hip arthroplasty (SuperPath) was proposed as an emerging minimally invasive and tissue sparing surgical technique [14]. This portal-assisted approach accesses the hip capsule superiorly through the interval between the gluteus medius and piriformis without dissecting any muscles or tendons [15, 16]. Available case series supported the SuperPath with encouraging postoperative outcomes, in terms of length of hospital stay (LOS), postoperative pain, range of motion (ROM), and recovery after surgery [14, 17, 18]. Despite the increasing clinical attention and utilization of the Superpath, outcome comparisons between the SuperPath and other traditional approaches (e.g. PLA) for THA was seldomly undertaken to specify convincing evidence of clinical benefits of this novel technique.

The present pilot study is aimed to compare the short-term outcomes of staged THA with the SuperPath and PLA for bilateral ONFH patients. We hypothesized that the SuperPath would yield superior outcomes over the PLA in terms of both the perioperative status (operation time, incision length, intraoperative blood loss, soft tissue damage, and length of hospital stay) and postoperative function (range of motion, pain, and hip function).

**Materials And Methods**

**Patients**

This research was approved by the Medical Ethics Committee of the West China Hospital, Sichuan University, Sichuan, China. Patients with bilateral ONFH was recruited from our department during March 2017 to March 2018. Subjects were included: (1) adult surgical candidates of bilateral THA for ONFH, (2) signed consent to be implanting of the specified prosthesis for the SuperPath, and (3) ability to complete scheduled postoperative 12 months follow-ups. Subjects were excluded with non-inflammatory degenerative joint diseases (e.g. osteoarthritis and posttraumatic arthritis), inflammatory joint diseases (e.g. reactive arthritis, ankylosing spondylitis, rheumatoid arthritis, and gout), inadequate neuromuscular status (e.g. prior paralysis and inadequate abductor strength), and overt infections or distant foci of infections.

**Surgical approach**

Operations were performed by a senior surgeon specialized in traumatology and lower limb reconstruction with over 15-year experience performing primary and revision THAs with the posterior approach (over 250 cases annually). The surgeon also has accomplished more than 50 SuperPath cases. Each patient underwent bilateral staged THA with one side SuperPath and the other side PLA with an average interval of 3 months. Both approaches were randomly performed in either right or left hips alternating within patients. The SuperPath was performed with specific prostheses (Microport Orthopedics, Arlington, TN, USA) as described by Chow et al. [19], and the PLA was accomplished with prostheses (DePuy Synthes, Warsaw, IN, USA) as described by Moore AT et al. [9].
Preoperative data were collected for each subject, including the age, gender, etiology, age of pain onset, history of hip injury/surgery, BMI, occupation category [20], American Society of Anesthesiologists (ASA) score [21], and Ficat stage [22]. Operation time was recorded from the initiation of incision to end of closure, and incision length was approximated with the linen tape along the surgical incision. The LOS, transfusion, complications, and readmission were also recorded.

Standardized patient care was provided including infection prophylaxis, venous thromboembolism prevention, nausea and vomiting management, wound care, and functional rehabilitation.

**Postoperative rehabilitation**

Identical rehabilitation program was undertaken for all patients after both SuperPath and PLA. Briefly, Immediate hip flexion, pneumatic compression with foot pumps, and deep breathing exercise were emphasized to minimize thromboembolic and pulmonary complications. After obtaining approvals from the physical therapists, patients began indoor walking independently with tolerated weight-bearing. Self-care and home-based rehabilitation were educated before discharge, in which patients were instructed to daily walk and gradually increase the walking distance towards a goal of 2 kilometers. All patients were generally discharged and allowed for walking with a cane on the postoperative day 3.

**Perioperative total blood loss**

Perioperative total blood loss was indirectly calculated from the change in the hematocrit (Hct) according to the Gross formula [23]:

\[
\text{Total blood loss} = \frac{\text{PBV} \times (\text{Hct}_{\text{pre}} - \text{Hct}_{\text{post}})}{\text{Hct}_{\text{ave}}}
\]

where \(\text{Hct}_{\text{pre}}\) is the initial preoperative Hct, \(\text{Hct}_{\text{post}}\) is the Hct on the morning of the postoperative day 3, and \(\text{Hct}_{\text{ave}}\) is the average of the \(\text{Hct}_{\text{pre}}\) and \(\text{Hct}_{\text{post}}\).

The patient’s blood volume (PBV, mL) was estimated according to the Nadler formula [24]:

\[
\text{PBV} = k_1 \times \text{height (m)} + k_2 \times \text{weight (kg)} + k_3
\]

where \(k_1 = 0.3669\), \(k_2 = 0.03219\), and \(k_3 = 0.6041\) for males; and \(k_1 = 0.3561\), \(k_2 = 0.03308\), and \(k_3 = 0.1833\) for females.

**Perioperative serum markers**
Serum markers are widely used to evaluate soft tissue damage in the hip arthroplasty [25–29] and mainly include the creatine kinase (CK), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). Levels of these serum markers were recorded for each patient on the day of hospital admission, postoperative day 1, day 3, and day 14, respectively.

**Acetabular component positioning analysis**

Standardized anteroposterior pelvic radiographs were acquired on the postoperative day 1. Inclination and anteversion angles were measured with a computer-assisted measurement system (Japan Medical Material, Osaka, Japan). Concisely, an ellipse was fitted to the rim of the acetabular shell on radiographs. Inclination angle was defined as the angle between the longitudinal axis of the body and the acetabular axis [30]. Anteversion angle was defined with the ratio between the lengths of the minor and major axes of the ellipse [31].

**Pain, range of motion, hip function, patient satisfaction**

The patient reported pain was measured with a visual analogue scale from 0 (no pain) to 10 (worst imaginable pain) at the day of hospital admission, postoperative day 1, day 3, day 14, 3 months, 6 months, and 12 months, respectively. The ROMs was recorded at the day before surgery, postoperative 3 months, 6 months, and 12 months. The Harris hip score (HHS) was determined for each patient at the day of hospital admission, postoperative day 1, day 3, day 14, 3 months, 6 months, and 12 months, respectively. Patient satisfaction was recorded based on the dichotomous responses (satisfied or unsatisfied) of each patient at the postoperative 3 months [32].

**Statistical analysis**

Values are expressed as mean ± standard deviation. Continuous data were analyzed with the Student's t-test and dichotomous data were assessed with the chi-square test. Any $P$ value < 0.05 was considered statistically significant. Calculations were performed using the SPSS (IBM SPSS 24; SPSS Inc., Chicago, IL).

**Results**

**Patient demographics and surgical details**

Four middle-aged (mean, 51 years old; range, 45–56 years) male patients was included with a mean BMI 21.49 kg/m$^2$ (range, 19.60–23.04 kg/m$^2$) (*Table 1*). All patients were diagnosed as bilateral ONFH (Ficat stage III or IV) induced by alcohol abuse and without history of hip injury/surgery.
The incision length in the SuperPath group (7.62 ± 0.97 cm) was significantly shorter than the PLA group (11.12 ± 1.21 cm, \( P = 0.049 \)) (Figure 1). However, the SuperPath group was associated with a significantly longer operation time (103.25 ± 12.41 min) than the PLA group (66.50 ± 13.79 min, \( P = 0.034 \)) (Table 2). The mean blood loss was also significantly higher in the SuperPath group (1108.50 ml) than in the PLA group (843.50 ml, \( P = 0.023 \)). Patients of both approaches received no blood transfusion and had a comparable length of hospital stay. No postoperative complications and readmission were reported within the 12 months follow-up.

**Perioperative serum markers change**

The serum markers, including CRP, CK, and ESR, showed equivalent trends in both approaches within 2 weeks postoperatively (Figure 2). Levels of all serum markers remained relatively higher in the SuperPath group than in the PLA group at each timing but without reaching statistical significances. Specially, both CK and CRP reached the maximal levels (SuperPath, 970.25 U/L, PLA, 899.50 U/L; SuperPath, 111.15 mg/L, PLA, 108.87 mg/L, respectively) at the postoperative day 3, while the ESR increased to the maximal level (SuperPath, 51.75 mm/h; PLA, 47.75 mm/h) at the postoperative day 1.

**Acetabular cup position**

Postoperative radiographs showed that the cup abduction angle was significantly lower in the SuperPath group (38.75°) than in the PLA group (44.50°, \( P = 0.035 \)) (Table 3). The average cup anteversion angle was comparable between the SuperPath (15.00°) and PLA (14.25°) groups.

**Range of motion**

The ROM of hips was significantly improved in both approaches compared with the baselines (Table S1). Specifically, the hip flexion in both Superpath and PLA groups was increased considerably from 94.75° and 90.25° preoperatively to 125.00° (\( P = 0.004 \)) and 124.75° (\( P = 0.054 \)) at 12 months postoperatively, respectively (Figure 3; Table S2). The hip abduction was also improved notably in both approaches (Superpath, 40.25°, \( P = 0.043 \); PLA, 41.25°, \( P = 0.011 \)) at 12 months postoperatively. Likewise, the hip adduction and external rotation were increased appreciably in both approaches at 12 months postoperatively. However, no significant differences of range of motion were identified between the two approaches at each timing within the postoperative 12 months (0.194 < \( P < 1.000 \)).

**Pain, hip function, and patient satisfaction**

The mean pain VAS of the SuperPath and PLA groups was significantly decreased from 8.25 and 8.00 preoperatively to 0.50 (\( P = 0.001 \)) and 0.25 (\( P = 0.001 \)) at 12 months postoperatively, respectively (Table S1). However, the differences of pain VAS were not significantly different between the two groups at all
timings within the postoperative 12 months (Figure 4; Table 4). The HHSs were significantly increased in both approaches (Superpath, 92.50, $P = 0.005$; PLA, 92.50, $P = 0.001$) at 12 months postoperatively compared with the baselines (Table S1). Intergroup comparisons showed that the PLA achieved a significantly improved hip function over the SuperPath with 15-point and 11-point increases at the postoperative day 14 ($P = 0.031$) and 3 months ($P = 0.025$), respectively (Table S3). However, the mean HHSs of both approaches were not significantly different at either the postoperative 6 or 12 months. Moreover, the dichotomous patients satisfactory score revealed that more patients were satisfied with the PLA (75%) rather than the SuperPath (25%), however, the difference of these data was not significant between both groups ($P = 0.157$) (Table 5).

**Discussion**

The present study identified that the SuperPath yielded significantly longer operation time, more total blood loss, deficient acetabular cup positioning, and inferior early-term hip function compared with the traditional posterolateral approach for total hip arthroplasty within 12-month postoperatively. Also, comparable outcomes of soft tissue damage, length of hospital stay, postoperative pain, range of motion, and patient satisfaction were disclosed between both approaches.

The definition of “a minimal invasive surgery” is still under debate, and the SuperPath might not be faithfully minimal invasive with more advantages than traditional approaches (e.g., the PLA) for total hip arthroplasty. Rachbauer and colleagues defined “a minimal invasive surgery” with the following characteristics: a short skin incision, preventing muscle splitting and/or detachment, and preserving the joint capsule [33]. Previous studies claimed that the SuperPath, as a true tissue-sparing minimally invasive approach, has less muscle damage mainly due to the preservation of external rotators [14, 17, 18, 34–36]. Our data discovered indeed a considerably shorter incision length in the SuperPath group, however, and identified a noticeably longer operation time ($P = 0.034$), more intraoperative blood loss ($P = 0.023$), and comparable extents of soft tissue damage in the SuperPath group compared with the PLA group ($0.099 < P < 0.928$) within the first 2 weeks postoperatively. Such unexpected outcomes with a trend towards lower patient satisfaction in the Superpath group are possibly attributed to the intraoperative mechanical stresses from the specific trocar cannula [37] and the elongated operation time [38–40].

Acetabular cup positioning impacts wear rates and long-term stability of the prostheses [41–43]. Biedermann et al. reported that hips dislocated posteriorly were less abducted than non-dislocating hips following the anterolateral approach and identified a statistically significant reduced dislocation risk from cups with 35°–55° abduction angle following the transgluteal approach [44]. The present study identified a significantly lower average abduction angle in the SuperPath group (38.75°) than in the PLA group (44.50°, $P = 0.035$), possibly hinting an increased dislocation risk in the long-term. However, these data were contracted with the only one available clinical trial from Xie et al. comparing the SuperPath and PLA for THA, which reported comparable abduction angles of 43.60° and 44.50° for both approaches [36]. Such a disagreement might be attributed to the relative poorer exposure during the SuperPath procedure,
hindering a proper intraoperative positioning of the acetabular component. Therefore, further studies with a greater sample size and longer follow-up might illustrate the possible variance of hip stability after both approaches.

Interestingly, equivalent pain and range of motion were witnessed between the SuperPath and PLA groups within 12 months postoperatively, therefore also contradicting with previous encouraging outcomes from the above-mentioned clinical trial from Xie and colleagues [36]. Noteworthily, the average operation time of PLA in Xie's study was 106.5 minutes (range, 90–133 minutes), which was considerably shorter than the professional preformation generally with a mean operation time within 60 minutes [45, 46]. Therefore, the encouraging outcomes of the SuperPath group are possibly attributed to their dissatisfied performance in the PLA controls.

Remarkably, the HHS demonstrated significantly impaired early-term hip function in the SuperPath group than in the PLA group. The HHS was 15-point (at the postoperative day 14) and 11-point (at the postoperative 3 months) lower in the SuperPath group compared with the PLA group and gradually approached comparable levels after 6 months postoperatively. One possible explanation of such impaired early-term hip function in the SuperPath group might be the significantly longer operation time and more total blood loss, which were previously reported as major factors influencing the functional recovery and quality of life of patients [47, 48].

Moreover, the learning curve of new technically demanding techniques need to be approvingly recognized, which is defined as the number of times an approach must be repeated before reaching a steady plateau. Compared with other approaches, the SuperPath is more subtle with changes in implant and instrument design and requires surgeons to augment performances via the fine-tuning with the learning curve [36]. The only clinical study has compared learning curves of the percutaneously assisted total hip arthroplasty (PATH) and SuperPath in terms of operation time [35]. However, a precise “learning curve” ought to be established in terms of short- and long-term outcomes instead of merely the operation time [49–51]. Hence, more randomized controlled trials are necessitated to define the minimum number of cases required to complete a learning curve of SuperPath.

Several limitations exist in the present study. Firstly, the sample size of the current study is greatly limited and the postoperative follow-up is relatively short, which might not allow us to draw a definitive conclusion of both approaches. Secondly, different hip implants were utilized in both groups, which might influence the final postoperative outcomes. However, the staged bilateral hip arthroplasty in identical individuals with a thoroughgoing self-comparison between the SuperPath and PLA and the significant differences of both preoperative status and short-term postoperative function opens up new questions for further comparisons of the SuperPath with other traditional THA approaches.

**Conclusions**

In summary, the SuperPath might not be truly minimal invasive with ultimate advantages over traditional posterolateral approach for THA. More randomized controlled trials are required to define the learning
curve of the SuperPath technique, in terms of postoperative outcomes, and to provide convincing
evidence of its clinical benefits over other traditional THA approaches.

**Abbreviations**

SuperPath: Supercapsular Percutaneously-assisted Total Hip; PLA: Posterolateral Approach; THA: Total
Hip Arthroplasty; ONFH: Osteonecrosis of the Femoral Head; LOS: Length of Hospital Stay; ROM: Range
of Motion; HHS: Harris Hip Score.

**Declarations**

**Ethics approval and consent to participate**

Ethical approval was obtained from the Institutional Review Board of the West China Hospital, Sichuan
University, Chengdu/Sichuan, P. R. China.

**Consent for publication**

Informed consent was obtained from all individual participants included in the study.

**Availability of data and materials**

The data supporting your findings can be found and have be presented within the manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

We gratefully acknowledge grants from the National Health and Family Planning Commission of the
People's Republic of China (No. 201302007) and the Sichuan Science and Technology Support Project
(No. 2018SZ0145; No. 2018SYZYF000). WKM acknowledges the financial support from the China
Scholarship Council.

**Authors’ contributions**

Conceptualization: WKM, LG and ZKZ; Surgery and data collection: WKM, GLW, HYW and ZYL; Data
analysis: ZH, WKM, HYW, DW, ZYL, YB, LG and ZKZ; Draft writing and proofreading: WKM, ZH, LG, GLW,
and ZKZ. All authors have read and approved the final manuscript.

References

1. Mont MA, Cherian JJ, Sierra RJ, Jones LC, Lieberman JR: Nontraumatic Osteonecrosis of the Femoral Head: Where Do We Stand Today? A Ten-Year Update. J Bone Joint Surg Am 2015, 97(19):1604–1627.

2. Banerjee S, Issa K, Pivec R, Kapadia BH, Khanuja HS, Mont MA: Osteonecrosis of the hip: treatment options and outcomes. Orthop Clin North Am 2013, 44(4):463–476.

3. Choi HR, Steinberg ME, E YC: Osteonecrosis of the femoral head: diagnosis and classification systems. Curr Rev Musculoskelet Med 2015, 8(3):210–220.

4. Zalavras CG, Lieberman JR: Osteonecrosis of the femoral head: evaluation and treatment. J Am Acad Orthop Surg 2014, 22(7):455–464.

5. Fukushima W, Fujioka M, Kubo T, Tamakoshi A, Nagai M, Hirota Y: Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res 2010, 468(10):2715–2724.

6. Kang JS, Park S, Song JH, Jung YY, Cho MR, Rhyu KH: Prevalence of osteonecrosis of the femoral head: a nationwide epidemiologic analysis in Korea. J Arthroplasty 2009, 24(8):1178–1183.

7. Lai YS, Wei HW, Cheng CK: Incidence of hip replacement among national health insurance enrollees in Taiwan. J Orthop Surg Res 2008, 3:42.

8. Laupacis A, Bourne R, Rorabeck C, Feeny D, Wong C, Tugwell P, Leslie K, Bullas R: The effect of elective total hip replacement on health-related quality of life. J Bone Joint Surg Am 1993, 75(11):1619–1626.

9. Moore AT: The self-locking metal hip prosthesis. J Bone Joint Surg Am 1957, 39-A(4):811–827.

10. Chechik O, Khashan M, Lador R, Salai M, Amar E: Surgical approach and prosthesis fixation in hip arthroplasty world wide. Arch Orthop Trauma Surg 2013, 133(11):1595–1600.

11. Hedlundh U, Hybbenette CH, Fredin H: Influence of surgical approach on dislocations after Charnley hip arthroplasty. J Arthroplasty 1995, 10(5):609–614.

12. Jolles BM, Bogoch ER: Posterior versus lateral surgical approach for total hip arthroplasty in adults with osteoarthritis. Cochrane Database Syst Rev 2004(1):CD003828.

13. Woo RY, Morrey BF: Dislocations after total hip arthroplasty. J Bone Joint Surg Am 1982, 64(9):1295–1306.

14. Chow J, Penenberg B, Murphy S: Modified micro-superior percutaneously-assisted total hip: early experiences & case reports. Curr Rev Musculoskelet Med 2011, 4(3):146–150.
15. Murphy SB, Ecker TM, Tannast M: *THA performed using conventional and navigated tissue-preserving techniques.* Clin Orthop Relat Res 2006, 453:160–167.

16. Penenberg BL, Bolling WS, Riley M: *Percutaneously assisted total hip arthroplasty (PATH): a preliminary report.* J Bone Joint Surg Am 2008, 90 Suppl 4:209–220.

17. Chow J, Fitch DA: *In-hospital costs for total hip replacement performed using the supercapsular percutaneously-assisted total hip replacement surgical technique.* Int Orthop 2017, 41(6):1119–1123.

18. Gofton W, Fitch DA: *In-hospital cost comparison between the standard lateral and supercapsular percutaneously-assisted total hip surgical techniques for total hip replacement.* Int Orthop 2016, 40(3):481–485.

19. Chow J: *SuperPath: The Direct Superior Portal-Assisted Total Hip Approach.* JBJS Essent Surg Tech 2017, 7(3):e23.

20. Virtanen M, Oksanen T, Pentti J, Ervasti J, Head J, Stenholm S, Vahtera J, Kivimaki M: *Occupational class and working beyond the retirement age: a cohort study.* Scand J Work Environ Health 2017, 43(5):426–435.

21. Schaeffer JF, Scott DJ, Godin JA, Attarian DE, Wellman SS, Mather RC, 3rd: *The Association of ASA Class on Total Knee and Total Hip Arthroplasty Readmission Rates in an Academic Hospital.* J Arthroplasty 2015, 30(5):723–727.

22. Ficat RP: *Idiopathic bone necrosis of the femoral head. Early diagnosis and treatment.* J Bone Joint Surg Br 1985, 67(1):3–9.

23. Gross JB: *Estimating allowable blood loss: corrected for dilution.* Anesthesiology 1983, 58(3):277–280.

24. Nadler SB, Hidalgo JH, Bloch T: *Prediction of blood volume in normal human adults.* Surgery 1962, 51(2):224–232.

25. Bergin PF, Doppelt JD, Kephart CJ, Benke MT, Graeter JH, Holmes AS, Haleem-Smith H, Tuan RS, Unger AS: *Comparison of minimally invasive direct anterior versus posterior total hip arthroplasty based on inflammation and muscle damage markers.* J Bone Joint Surg Am 2011, 93(15):1392–1398.

26. Poehling-Monaghan KL, Taunton MJ, Kamath AF, Trousdale RT, Sierra RJ, Pagnano MW: *No Correlation Between Serum Markers and Early Functional Outcome After Contemporary THA.* Clin Orthop Relat Res 2017, 475(2):452–462.

27. De Anta-Diaz B, Serralta-Gomis J, Lizaur-Utrilla A, Benavidez E, Lopez-Prats FA: *No differences between direct anterior and lateral approach for primary total hip arthroplasty related to muscle damage or functional outcome.* Int Orthop 2016, 40(10):2025–2030.
28. Fink B, Mittelstaedt A, Schulz MS, Sebena P, Singer J: *Comparison of a minimally invasive posterior approach and the standard posterior approach for total hip arthroplasty: A prospective and comparative study*. J Orthop Surg Res 2010, 5:46.

29. Suzuki K, Kawachi S, Sakai H, Nanke H, Morita S: *Mini-incision total hip arthroplasty: a quantitative assessment of laboratory data and clinical outcomes*. J Orthop Sci 2004, 9(6):571–575.

30. Murray DW: *The definition and measurement of acetabular orientation*. J Bone Joint Surg Br 1993, 75(2):228–232.

31. Widmer KH: *A simplified method to determine acetabular cup anteversion from plain radiographs*. J Arthroplasty 2004, 19(3):387–390.

32. Frank RP, Milgrom P, Leroux BG, Hawkins NR: *Treatment outcomes with mandibular removable partial dentures: a population-based study of patient satisfaction*. J Prosthet Dent 1998, 80(1):36–45.

33. Rachbauer F, Kain MS, Leunig M: *The history of the anterior approach to the hip*. Orthop Clin North Am 2009, 40(3):311–320.

34. Cronin MD, Gofton W, Erwin L, Fitch DA, Chow J: *Early surgical and functional outcomes comparison of the supercapsular percutaneously-assisted total hip and traditional posterior surgical techniques for total hip arthroplasty: protocol for a randomized, controlled study*. Ann Transl Med 2015, 3(21):335.

35. Rasuli KJ, Gofton W: *Percutaneously assisted total hip (PATH) and Supercapsular percutaneously assisted total hip (SuperPATH) arthroplasty: learning curves and early outcomes*. Ann Transl Med 2015, 3(13):179.

36. Xie J, Zhang H, Wang L, Yao X, Pan Z, Jiang Q: *Comparison of supercapsular percutaneously assisted approach total hip versus conventional posterior approach for total hip arthroplasty: a prospective, randomized controlled trial*. J Orthop Surg Res 2017, 12(1):138.

37. Capone A, Podda D, Civinini R, Gusso MI: *The role of dedicated instrumentation in total hip arthroplasty*. J Orthop Traumatol 2008, 9(2):109–115.

38. Ogonda L, Wilson R, Archbold P, Lawlor M, Humphreys P, O'Brien S, Beverland D: *A minimal-incision technique in total hip arthroplasty does not improve early postoperative outcomes. A prospective, randomized, controlled trial*. J Bone Joint Surg Am 2005, 87(4):701–710.

39. Mayer C, Franz A, Harmsen JF, Queitsch F, Behringer M, Beckmann J, Krauspe R, Zilkens C: *Soft-tissue damage during total knee arthroplasty: Focus on tourniquet-induced metabolic and ionic muscle impairment*. J Orthop 2017, 14(3):347–353.

40. Kwak S, Chun Y, Rhyu K, Cha J, Cho Y: *Quantitative analysis of tissue injury after minimally invasive total hip arthroplasty*. Clin Orthop Surg 2014, 6(3):279–284.
41. Soong M, Rubash HE, Macaulay W: *Dislocation after total hip arthroplasty*. *J Am Acad Orthop Surg* 2004, 12(5):314–321.

42. Lewinnek GE, Lewis JL, Tarr R, Compere CL, Zimmerman JR: *Dislocations after total hip-replacement arthroplasties*. *J Bone Joint Surg Am* 1978, 60(2):217–220.

43. Hamilton WG, Parks NL, Huynh C: *Comparison of Cup Alignment, Jump Distance, and Complications in Consecutive Series of Anterior Approach and Posterior Approach Total Hip Arthroplasty*. *J Arthroplasty* 2015, 30(11):1959–1962.

44. Biedermann R, Tonin A, Krismer M, Rachbauer F, Eibl G, Stockl B: *Reducing the risk of dislocation after total hip arthroplasty: the effect of orientation of the acetabular component*. *J Bone Joint Surg Br* 2005, 87(6):762–769.

45. Spaans AJ, van den Hout JA, Bolder SB: *High complication rate in the early experience of minimally invasive total hip arthroplasty by the direct anterior approach*. *Acta Orthop* 2012, 83(4):342–346.

46. Poehling-Monaghan KL, Kamath AF, Taunton MJ, Pagnano MW: *Direct anterior versus miniposterior THA with the same advanced perioperative protocols: surprising early clinical results*. *Clin Orthop Relat Res* 2015, 473(2):623–631.

47. Guo WJ, Wang JQ, Zhang WJ, Wang WK, Xu D, Luo P: *Hidden blood loss and its risk factors after hip hemiarthroplasty for displaced femoral neck fractures: a cross-sectional study*. *Clin Interv Aging* 2018, 13:1639–1645.

48. Yang Y, Yong-Ming L, Pei-jian D, Jia L, Ying-ze Z: *Leg position influences early blood loss and functional recovery following total knee arthroplasty: A randomized study*. *Int J Surg* 2015, 23(Pt A):82–86.

49. D’Arrigo C, Speranza A, Monaco E, Carcangi A, Ferretti A: *Learning curve in tissue sparing total hip replacement: comparison between different approaches*. *J Orthop Traumatol* 2009, 10(1):47–54.

50. Seng BE, Berend KR, Ajluni AF, Lombardi AV, Jr.: *Anterior-supine minimally invasive total hip arthroplasty: defining the learning curve*. *Orthop Clin North Am* 2009, 40(3):343–350.

51. Archibeck MJ, White RE, Jr.: *Learning curve for the two-incision total hip replacement*. *Clin Orthop Relat Res* 2004(429):232–238.

**Tables**

| Table 1. Demographic characteristics of patients. |
### Parameters

| Parameters                  | SuperPath          | PLA            | P value |
|-----------------------------|--------------------|----------------|---------|
| Age (years)                 | 51.00 ± 4.54       | 51.00 ± 4.54   |         |
| Gender (%)                  | Male (100%)        | Male (100%)    |         |
| BMI (kg/m²)                 | 21.49 ± 1.73       | 21.49 ± 1.73   |         |
| Etiology                    | Alcohol abuse      | Alcohol abuse  |         |
| History of hip injury       | n.a.               | n.a.           |         |
| History of hip surgery      | n.a.               | n.a.           |         |
| ASA grade                   | 1.66 ± 0.58        | 1.66 ± 0.58    |         |
| Age of pain onset (years)   |                    |                |         |
| Left                        | 3.00 ± 1.41        | 2.50 ± 0.71    |         |
| Right                       | 3.50 ± 2.12        | 2.50 ± 2.12    |         |
| Ficat stage                 |                    |                |         |
| III                         | 2                  | 1              |         |
| IV                          | 2                  | 3              |         |
| Surgical side               |                    |                |         |
| Left                        | 2                  | 2              |         |
| Right                       | 2                  | 2              |         |
| Postoperative complication  | n.a.               | n.a.           |         |
| Readmission                 | n.a.               | n.a.           |         |

ASA, American Society of Anesthesiologists; BMI, body mass index; ONFH, Osteonecrosis of the femoral head; PLA, posterolateral approach; SuperPath, Supercapsular Percutaneously-Assisted Total Hip; L, left hip; R, right hip; n.a., not applicable.

**Table 2.** Perioperative data.
Values are expressed as mean± standard deviation. PLA, posterolateral approach; SuperPath, supercapsular percutaneously-assisted total hip arthroplasty; n.a., not applicable.

**Table 3.** Radiologic evaluation of acetabular cup positioning.

| Parameters               | SuperPath       | PLA            | P value |
|--------------------------|-----------------|----------------|---------|
| Abduction angle (degrees)| 38.75 ± 8.21    | 44.50 ± 3.64   | 0.035*  |
| Anteversion angle (degrees) | 15.00 ± 1.82  | 14.25 ± 2.06  | 0.638   |

Values are expressed as mean± standard deviation. PLA, posterolateral approach; SuperPath, supercapsular percutaneously-assisted total hip arthroplasty.

**Table 4.** Pain VAS and HHS.

| Parameters | Timings          | SuperPath       | PLA            | P value |
|------------|------------------|-----------------|----------------|---------|
| Pain VAS   | preop            | 8.25 ± 0.95     | 8.00 ± 0.81    | 0.391   |
|            | postop day 1     | 8.25 ± 0.95     | 7.00 ± 0.81    | 0.080   |
|            | postop day 3     | 7.00 ± 1.41     | 6.50 ± 0.57    | 0.638   |
|            | postop day 14    | 5.50 ± 1.29     | 4.25 ± 1.25    | 0.239   |
|            | postop 3 months  | 2.25 ± 0.50     | 1.75 ± 0.50    | 0.182   |
|            | postop 6 months  | 0.75 ± 0.50     | 0.75 ± 0.50    | n.a     |
|            | postop 12 months | 0.50 ± 0.57     | 0.25 ± 0.50    | 0.638   |
| HHS        | preoperative     | 37.86 ± 13.27   | 37.66 ± 7.02   | 0.963   |
|            | postop day 14    | 62.50 ± 8.34    | 77.50 ± 3.41   | 0.031   |
|            | postop 3 months  | 72.25 ± 3.86    | 83.25 ± 2.36   | 0.025   |
|            | postop 6 months  | 84.25 ± 6.18    | 86.75 ± 3.86   | 0.774   |
|            | postop 12 months | 92.50 ± 1.73    | 92.50 ± 1.73   | n.a.    |
Values are expressed as mean ± standard deviation. HHS, Harris hip score; PLA, posterolateral approach; SuperPath, Supercapsular Percutaneously-Assisted Total Hip; VAS, visual analogue scale; n.a., not applicable.

### Table 5. Satisfaction of patients.

|                | SuperPath | PLA | $\chi^2$ | P value |
|----------------|-----------|-----|----------|---------|
| Satisfaction   | 1         | 3   | 2.000    | 0.157   |
| Non-Satisfaction| 3         | 1   |          |         |

PLA, posterolateral approach; SuperPath, Supercapsular Percutaneously-Assisted Total Hip.

### Figures

![Figure 1](image)

**Figure 1**
Comparisons of perioperative data. Compared with the PLA group, the SuperPath group was associated with significantly shorter incision length, but drastically longer operation time and more total blood loss. Patients of both approaches obtained a comparable length of hospital stay.

![Figure 2](image)

**Figure 2**

Perioperative serum markers change. Levels of serum CK, CRP, and ESR remained relatively higher in the SuperPath group than in the PLA group at each timing but without reaching statistical significances. Both CRP and CK reached their maximum at the postoperative day 3, while the ESR increased to the maximum at the postoperative day 1.
Figure 3

Range of motion. No significant differences of ROM were identified between the two approaches at all timings within the postoperative 12 months.
Figure 4

Pain VAS and Harris Hip Score. The pain VAS was not significantly different between both groups at all timings within the postoperative 12 months. The HHSs were significantly improved in the SuperPath group over the PLA group at both 14 days and 3 months postoperatively and reached a comparable level after 6 months postoperatively between groups.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- supplement1.docx
- supplement2.doc